KAPA Kairos Pharma, LTD.

CIK 0001962011 30 ready 8-Ks latest August 21, 2026, 4:30 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 30

Latest filing August 21, 2026, 4:30 PM ET

Top materiality 0.80

Event mix other_material ×25 · m_and_a ×3 · leadership ×1

Sentiment 15 pos · 0 neg · 15 neu

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for KAPA

Highest-materiality recent filing

Kairos Pharma acquires exclusive worldwide rights to CL-273 from Celyn Therapeutics

March 2, 2026, 6:59 PM ET M&A materiality 0.80 positive item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Acquired 100% worldwide rights to CL-273, a pan-EGFR inhibitor for EGFR-mutant NSCLC, from Celyn Therapeutics (backed by OrbiMed and Torrey Pines).
Consideration includes 16.5% of Kairos shares on fully diluted basis, $15M milestone upon FDA submission, and 2% royalty on U.S. net revenues.

Read filing →

August 21, 2026, 4:30 PM ET other material materiality 0.50 neutral item 3.03 item 5.03 item 7.01 item 9.01

Kairos Pharma announces 1-for-7 reverse stock split effective Sept 1, 2026

1-for-7 reverse split effective Sep 1, 2026 at 12:01 a.m. ET; trading under KAPA with new CUSIP 48301N203.
July 22, 2026, 8:35 AM ET other material materiality 0.60 positive item 1.01 item 8.01 item 9.01

Kairos Pharma collaborates with Bayer to test ENV-105 + XOFIGO in mCRPC; market up to $1.3B

Bayer to supply radium for Kairos' study of ENV-105 (carotuximab) with XOFIGO in metastatic castration-resistant prostate cancer.
July 15, 2026, 8:30 AM ET other material materiality 0.65 positive item 8.01 item 9.01

Kairos Pharma reports zero Grade 3+ toxicities from ENV-105 in Phase 1 NSCLC trial

Zero Grade 3+ toxicities from ENV-105 in 13 patients with advanced EGFR-mutated NSCLC.
June 30, 2026, 5:19 PM ET other material materiality 0.50 neutral item 5.07

Kairos Pharma shareholders approve reverse stock split and equity plan amendments

Stockholders approved reverse stock split at ratio between 1:3 and 1:250, with board discretion on timing.
June 4, 2026, 8:00 AM ET M&A materiality 0.55 positive item 8.01 item 9.01

Kairos Pharma signs term sheet to acquire CL-741, a Phase 1-ready c-MET inhibitor; outlines 2026 milestones

Acquiring worldwide rights to CL-741, an oral type IIb c-MET kinase inhibitor targeting EGFR-mutated lung cancer and esophageal/gastric cancers.
May 18, 2026, 8:31 AM ET other material materiality 0.15 neutral item 8.01 item 9.01

Kairos Pharma issues investor presentation for LD Micro Invitational; no material new data disclosed

Company issued investor presentation for presentation at LD Micro Invitational on May 18-19, 2026.
March 2, 2026, 6:59 PM ET M&A materiality 0.80 positive item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Kairos Pharma acquires exclusive worldwide rights to CL-273 from Celyn Therapeutics

Acquired 100% worldwide rights to CL-273, a pan-EGFR inhibitor for EGFR-mutant NSCLC, from Celyn Therapeutics (backed by OrbiMed and Torrey Pines).
February 26, 2026, 6:59 PM ET M&A materiality 0.50 positive item 8.01 item 9.01

Kairos Pharma signs term sheet to acquire two lung cancer assets from Celyn Therapeutics

Worldwide rights to CL-273 (pre-IND pan-EGFR inhibitor) and CL-741 (Phase 1-ready c-MET inhibitor) for NSCLC.
October 15, 2025, 7:59 PM ET other material materiality 0.35 neutral item 5.02 item 9.01

Kairos Pharma grants $950K RSUs to executives; $227.5K cash bonuses for FY2024

Total RSU grant value $950K at $1.31/share, vesting Oct 8, 2026 with change-of-control acceleration.
October 7, 2025, 7:59 PM ET other material materiality 0.70 positive item 1.01 item 8.01 item 9.01

Kairos Pharma to Present Phase 2 Prostate Cancer Data at ESMO 2025

On October 7, 2025, Kairos issued press release announcing ESMO Congress presentation in Berlin from October 17-21.
September 18, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01 item 9.01

Kairos Pharma reports positive Phase 2 interim efficacy for ENV105 in mCRPC; median PFS >13 months

Median PFS >13 months in 8 evaluable patients with mCRPC who failed prior hormone therapy.
September 11, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Kairos Pharma to host KOL event Sept 18 for ENV105 Phase 2 interim efficacy data

Virtual KOL event on Sept 18, 2025, at 5 p.m. ET to discuss interim efficacy results from ENV105 Phase 2 trial in advanced prostate cancer.
September 3, 2025, 7:59 PM ET other material materiality 0.50 neutral item 8.01 item 9.01

Kairos Pharma to present initial Phase 1 data for ENV105 in NSCLC at World Lung Cancer Conference

Dr. Karen Reckamp to present combination of ENV105 (carotuximab) with osimertinib for advanced EGFR-mutated NSCLC.
July 15, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Kairos Pharma reports positive safety results from Phase 2 ENV-105 trial in mCRPC

No dose-limiting toxicities or unexpected adverse events in first 10 patients.
June 12, 2025, 7:59 PM ET other material materiality 0.45 neutral item 1.01 item 5.07 item 9.01

Kairos Pharma shareholders approve dilutive stock issuance, elect directors, enter IR pact

Entered one-year IR services agreement with Barretto Pacific Corp for $170,000 fee.
June 3, 2025, 7:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

Kairos Pharma presents KROS101 preclinical data at ASCO; shows superiority over TRX518

KROS101 is a small molecule GITR ligand agonist with dual mechanisms: promotes T effector proliferation and reduces T reg suppression.
April 28, 2025, 7:59 PM ET other material materiality 0.55 neutral item 4.01 item 9.01 ◈ Auditor Changes ×2

Kairos Pharma replaces auditor Marcum with Weinberg; 2023 report had going concern

Audit committee dismissed Marcum LLP and appointed Weinberg & Company effective April 23, 2025.
April 24, 2025, 7:59 PM ET other material materiality 0.50 neutral item 8.01 item 9.01

Kairos Pharma CEO letter updates ENV105 trials, DoD grant, and analyst coverage

ENV105 in Phase 2 prostate cancer and Phase 1 lung cancer trials; interim efficacy data expected end of Q2 2025.
March 20, 2025, 7:59 PM ET other material materiality 0.35 positive item 8.01 item 9.01

Kairos Pharma publishes study showing CD105 blockade restores osimertinib sensitivity in NSCLC

Study in Drug Resistance Updates shows CD105 upregulation drives resistance to EGFR-targeted therapy osimertinib.
February 26, 2025, 6:59 PM ET other material materiality 0.55 positive item 8.01 item 9.01

Kairos Pharma presents preclinical data for KROS 101 and KROS 401 at AACR IO

KROS 101 (GITR agonist) inhibited tumor growth in melanoma model and increased CD4+/CD8+ T cell proliferation.
February 6, 2025, 6:59 PM ET other material materiality 0.35 positive item 8.01 item 9.01

Kairos Pharma presents preclinical data on KROS 101 at AACR-JCA; shows tumor reduction in melanoma models

KROS 101, a GITR agonist, enhanced T cell infiltration and proliferation in mouse melanoma models and human glioblastoma in vitro.
January 17, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 9.01

Kairos Pharma closes $3.5M PIPE offering of pre-funded units and warrants

Sold 2,500,000 Pre-Funded Units at $1.399/unit, raising gross proceeds of $3,497,500.
January 14, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 9.01

Kairos Pharma raises $3.5M in PIPE offering at $1.40/unit with warrants

Raises $3.5M gross from sale of units at $1.40/Common Unit and $1.399/Pre-Funded Unit.
December 13, 2024, 6:59 PM ET leadership materiality 0.50 positive item 5.02 item 9.01

Kairos Pharma appoints Rahul Singhvi as director, replacing Rosemary Mazanet

Dr. Rosemary Mazanet resigned from board effective upon appointment of new independent director; not due to disagreement.
November 19, 2024, 6:59 PM ET other material materiality 0.30 neutral item 7.01 item 9.01

Kairos Pharma approved for dual listing on Upstream; trading starts Nov 26

Approved to dual list shares on Upstream, a MERJ Exchange market and global trading app.
October 10, 2024, 7:59 PM ET other materiality 0.10 neutral item 8.01 item 9.01

Kairos Pharma CEO to speak at Maxim Healthcare Virtual Summit; investor deck updated

CEO Dr. John S. Yu will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit (Oct 15-17).
October 4, 2024, 7:59 PM ET other material materiality 0.55 neutral item 1.01 item 9.01

Kairos Pharma enters consulting pact with Cross Current for $700K total compensation

Consulting agreement for $200,000 cash and restricted shares valued at $500,000, subject to a six-month true-up to maintain $500K value.
September 27, 2024, 7:59 PM ET other material materiality 0.45 neutral item 1.01 item 9.01

Kairos Pharma enters two service agreements: $615K cash + 50K RSUs

CEO.CA Technologies to provide advertising and consulting for $250,000 over 12 months.
September 24, 2024, 7:59 PM ET other material materiality 0.60 positive item 1.01 item 8.01 item 9.01

Kairos Pharma enters $900K biomarker agreement with PreCheck for ENV105 trials

Agreement with PreCheck Health Services for biomarker screening in ongoing lung (NCT05401110) and prostate (NCT05534646) cancer trials.
September 17, 2024, 7:59 PM ET other material materiality 0.80 positive item 1.01 item 7.01 item 9.01

Kairos Pharma closes $6.2M IPO; shares trade on NYSE American under KAPA

Closed IPO of 1,550,000 shares at $4.00/share; gross proceeds $6,200,000.

Materiality & sentiment trend

Max materiality 0.80 · Median 0.55 · Most common event other_material

15 positive 0 negative 15 neutral

source · KAPA on sec.gov